You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Infectious Diseases
Appili Therapeutics and Vitalex Biosciences secure NIAID contract for fungal vaccine development for up to USD40m
Login
Username:

Password:


Related Headlines

Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy

Senhwa Biosciences reports first patient dosed in Pidnarulex (CX-5461) study in patients with advanced solid tumours

Centivax raises USD45m to commercialise universal flu vaccine

SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval 

INOVIO prices USD25m public offering

Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC

Seegene launches STAgora infectious disease analytics platform

hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results

Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement

Oxurion signs LOI to acquire majority stake in preclinical microbiology CRO

bioMérieux acquires Day Zero Diagnostics assets to expand rapid sequencing diagnostics

EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement

FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea

Ondine's Steriwave proven effective against deadly Mucor fungus

Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025